Engineered counter acting agent may forestall Covid from contaminating human cells Kumar Jeetendra | November 4, 2020 By screening hundreds of artificial antibodies, researchers at Karolinska Institutet in Sweden and EMBL Hamburg in Germany have identified an antibody that may prevent the new coronavirus from infecting human cells. The analysis, which is printed in the journal Nature Communications, also reveals how electrons can be quickly generated in the event of future pandemics. …
Researchers grow new serological assay for discovery of SARS-CoV-2 antibodies Kumar Jeetendra | December 13, 2020 Researchers at UC Santa Cruz have developed a novel serological assay for the detection of antibodies to SARS-CoV-2, the coronavirus which causes COVID-19. Rebecca DuBois, associate professor of biomolecular engineering at UC Santa Cruz, said the new method her staff developed is as accurate as the most dependable antibody tests now available, but is less …
National consortium to examine the impacts of arising SARS-CoV-2 mutations Kumar Jeetendra | January 16, 2021 The’G2P-UK’ National Virology Consortium will study how mutations in the virus affect key outcomes like how transmissible it is, the seriousness of COVID-19 it causes, and the potency of vaccines and treatments. The Consortium will bring together leading virologists from 10 research institutions. They will work together with the COVID-19 Genomics UK (COG-UK) consortium, which …
Killing antibodies actuated by COVID-19 vaccines less successful against new variants Kumar Jeetendra | March 15, 2021 SARS-CoV-2, the virus that causes COVID-19, has mutated through the pandemic. New variants of this virus have arisen around the world, including variants that might possess increased capacity to spread or evade the immune system. Such variations have been identified in California, Denmark, the U.K., South Africa and Brazil/Japan. Recognizing how well the COVID-19 vaccines …
Small SARS-CoV-2 protein may have huge ramifications for future COVID-19 medicines Kumar Jeetendra | April 12, 2021 A very small protein of SARS-CoV-2, the coronavirus that gives rise to COVID-19, may have big implications for future therapies, according to a team of Penn State researchers. Using a novel toolkit of approaches, the scientists uncovered the first full structure of the Nucleocapsid (N) protein and discovered how antibodies from COVID-19 patients interact with …
Novel antibody candidate shows powerful binding to different SARS-CoV-2 variant mutations Kumar Jeetendra | September 25, 2021 Twist Bioscience Corporation today reported that its internally-discovered antibody candidate TB202-3 (CoVIC-094), demonstrated potent binding to diverse SARS-CoV-2 variant mutations, including strains with the E484K, N501Y, D614G, Y453F and K417N mutations in pseudovirus assays, indicating this therapeutic antibody may be effective in treating many strains of COVID-19. The Coronavirus Immunotherapy Consortium (CoVIC) is an academic-industry-non-profit …
Nano-bubbles containing ACE2 protein can hinder contamination from wide strains of SARS-CoV-2 Kumar Jeetendra | January 21, 2022 Northwestern Medicine and The University of Texas MD Anderson Cancer Center discovered that natural nano-bubbles containing ACE2 protein (evACE2) were found in the blood of COVID-19 victims. They also discovered that these particles could block infection by broad strains of SARS/CoV-2 virus. Scientists said that the evACE2 acts in the body as a decoy and …
